Julia Chapman
Senior Vice President of OperationsMs. Julia Chapman was Senior Vice President of Program & Portfolio Management of Latigo Biotherapeutics, Inc. from 2025 until March 2026 and serves as Senior Vice President of Operations since March 2026. Ms. Chapman served as Senior Vice President of Corporate Strategy and Partnerships of Verve Therapeutics, Inc. from October 2022 and 2023 respectively until September 2023 and had been its Senior Vice President of Planning since October 2022 until 2023. Ms. Chapman is a biotech executive and advisor with a successful track record leading program, portfolio and commercial strategy for novel therapeutic modalities. Through leadership roles at Novartis, Precision Biosciences and BridgeBio, she has facilitated research and development of more than 20 therapies spanning vaccines, RNA medicines, cell and gene therapy and gene-editing. Most recently, as Vice President of Business Development and Strategy at BridgeBio, she led development of AAV gene therapies for CNS, renal and metabolic diseases, as well as Partnerships to develop next-generation delivery technologies. Prior to Bridge, she led portfolio strategy and alliance management at Precision Biosciences where she supported successful Series B and IPO rounds, as well as development of Partnerships with Gilead, Shire and the University of Pennsylvania. Here, she developed in-depth knowledge of Familial Hypercholesterolemia and atherosclerotic cardiovascular disease as Precision’s portfolio included in vivo liver gene editing of PCSK9 and ANGPTL3 using meganuclease technology. She spent her early career at Novartis in various roles of increasing responsibility within the TechOps, Development and Commercial Organizations and in multiple geographies, including the UK, Germany, Italy and Switzerland. During her tenure at Novartis, her projects included Global Pandemic Planning, late-stage development of adjuvanted and quadrivalent vaccines, early-stage development of the SAM vaccine and cross-functional M&A workstreams to support transactions with GSK and CSL. She holds a B.S.E. in Biomedical Engineering and an MBA from Duke University.
Positions
- Company NameLatigo Biotherapeutics, Inc.Stock CodeLTGOPositionSenior Vice President of OperationsColleagues
- NKNeha KrishnamohanChief Business Officer & CFO
- TPTimothy P. WalbertIndependent Chairman
- NFNima FarzanExecutive Officer
- NKNeil Kumar SinglaChief Medical Officer
- TNTodd N. SmithPresIdent, CEO & Director
- BCBeth C. SeidenbergIndependent Director
- SMSara M. BonsteinIndependent Director
- DPDeborah PalestrantIndependent Director
